Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Down 80.5% in March

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 36,100 shares, a drop of 80.5% from the February 28th total of 184,900 shares. Based on an average trading volume of 99,800 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.5% of the company’s stock are short sold.

Institutional Trading of Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned about 0.59% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Creative Medical Technology Stock Up 0.5 %

CELZ traded up $0.01 on Wednesday, reaching $2.21. The company had a trading volume of 278,987 shares, compared to its average volume of 41,285. The stock has a 50-day moving average price of $3.77 and a 200-day moving average price of $3.25. The stock has a market capitalization of $3.86 million, a PE ratio of -0.58 and a beta of 1.70. Creative Medical Technology has a 1 year low of $1.91 and a 1 year high of $6.90.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.